Literature DB >> 32986675

Quantitative Study of the Changes in Cerebral Blood Flow and Iron Deposition During Progression of Alzheimer's Disease.

Dongxue Li1, Yuancheng Liu1, Xianchun Zeng1, Zhenliang Xiong1, Yuanrong Yao2, Daiyi Liang2, Hao Qu2, Hui Xiang3, Zhenggui Yang3, Lisha Nie4, Pu-Yeh Wu4, Rongpin Wang1.   

Abstract

BACKGROUND: Advanced Alzheimer's disease (AD) has no effective treatment, and identifying early diagnosis markers can provide a time window for treatment.
OBJECTIVE: To quantify the changes in cerebral blood flow (CBF) and iron deposition during progression of AD.
METHODS: 94 subjects underwent brain imaging on a 3.0-T MRI scanner with techniques of three-dimensional arterial spin labeling (3D-ASL) and quantitative susceptibility mapping (QSM). The subjects included 22 patients with probable AD, 22 patients with mild cognitive impairment (MCI), 25 patients with subjective cognitive decline (SCD), and 25 normal controls (NC). The CBF and QSM values were obtained using a standardized brain region method based on the Brainnetome Atlas. The differences in CBF and QSM values were analyzed between and within groups using variance analysis and correlation analysis.
RESULTS: CBF and QSM identified several abnormal brain regions of interest (ROIs) at different stages of AD (p < 0.05). Regionally, the CBF values in several ROIs of the AD and MCI subjects were lower than for NC subjects (p < 0.001). Higher QSM values were observed in the globus pallidus. The CBF and QSM values in multiple ROI were negatively correlated, while the putamen was the common ROI of the three study groups (p < 0.05). The CBF and QSM values in hippocampus were cross-correlated with scale scores during the progression of AD (p < 0.05).
CONCLUSION: Iron deposition in the basal ganglia and reduction in blood perfusion in multiple regions existed during the progression of AD. The QSM values in putamen can be used as an imaging biomarker for early diagnosis of AD.

Entities:  

Keywords:  3D-arterial spin labeling; Alzheimer’s disease; Brainnetome Atlas; quantitative susceptibility mapping

Year:  2020        PMID: 32986675     DOI: 10.3233/JAD-200843

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

Review 1.  Early differentiation of neurodegenerative diseases using the novel QSM technique: what is the biomarker of each disorder?

Authors:  Farzaneh Nikparast; Zohreh Ganji; Hoda Zare
Journal:  BMC Neurosci       Date:  2022-07-28       Impact factor: 3.264

Review 2.  The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.

Authors:  Ke-Ru Li; An-Guo Wu; Yong Tang; Xiao-Peng He; Chong-Lin Yu; Jian-Ming Wu; Guang-Qiang Hu; Lu Yu
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

3.  Brain oxygen extraction and neural tissue susceptibility are associated with cognitive impairment in older individuals.

Authors:  Gloria C Chiang; Junghun Cho; Jonathan Dyke; Hang Zhang; Qihao Zhang; Michael Tokov; Thanh Nguyen; Ilhami Kovanlikaya; Michael Amoashiy; Mony de Leon; Yi Wang
Journal:  J Neuroimaging       Date:  2022-03-16       Impact factor: 2.324

Review 4.  Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?

Authors:  Farzaneh Nikparast; Zohreh Ganji; Mohammad Danesh Doust; Reyhane Faraji; Hoda Zare
Journal:  Insights Imaging       Date:  2022-04-13

Review 5.  Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions.

Authors:  Chen Ma; Fenfang Hong; Shulong Yang
Journal:  Molecules       Date:  2022-02-11       Impact factor: 4.411

6.  Application of Three-Dimensional Pseudocontinuous Arterial Spin Labeling Perfusion Imaging in the Brains of Children With Autism.

Authors:  Shilong Tang; Xianfan Liu; Qiying Ran; Lisha Nie; Lan Wu; Zhengxia Pan; Ling He
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.